Novo Nordisk (NVO) ADRs traded lower on Tuesday after the Danish drugmaker reported mixed results for 2025 and initiated its 2026 outlook.
The company reported DKK 309.1B in sales for 2025, exceeding the DKK 307.6B projected by analysts, according to Bloomberg data.
However, its adjusted EBIT and net income for the period trailed expectations, standing at DKK 127.7B and DKK 102.4B compared to DKK 129.6B and DKK 103.3B in the consensus, respectively.
The pharma giant projected its 2026 sales and operating profit to decline 5% YoY–13% YoY on a forex-adjusted basis in comparison to the nearly 1.4% YoY and ~3.1% YoY projected by analysts, respectively.
The weight loss drugmaker also proposed a final dividend of DKK 7.95 per share for 2025 and launched a new share buyback program worth up to DKK 15B.
